Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHIT1 | Q13231 | 2/20 | 0.37 |
| ▸ | CHIA | Q9BZP6 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 6/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL581154 | 0.82 | CHIT1 (0.43) | CHIT1CHIATACR1PSEN1PSEN2 | |
| SCHEMBL586739 | 0.80 | OPRK1 (0.50) | CHIT1CHIATACR1OPRK1MAPT | |
| SCHEMBL580852 | 0.74 | PSEN1 (0.49) | TACR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3073152 | 0.74 | MAPT (0.45) | CHIT1CHIAMAPTTSHR | |
| SCHEMBL3069164 | 0.74 | MAPT (0.45) | CHIT1CHIAMAPTTSHR | |
| SCHEMBL582142 | 0.74 | MAPT (0.45) | CHIT1CHIAMAPTTSHR | |
| SCHEMBL8481125 | 0.73 | TACR1 (0.50) | CHIT1CHIATACR1OPRK1CCR5 | |
| SCHEMBL8481128 | 0.73 | TACR1 (0.50) | CHIT1CHIATACR1OPRK1CCR5 | |
| SCHEMBL580834 | 0.71 | NOTUM (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL581453 | 0.70 | PLG (0.42) | CHIT1CHIATACR1OPRK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| EP-2417131-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117323-A1 | METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | CHIT1 3687/4885CHIA 3540/4885TACR1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.